Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura

H. B. Feys, N. Vandeputte, R. Palla, F. Peyvandi, K. Peerlinck, H. Deckmyn, H. R. Lijnen, K. Vanhoorelbeke

Research output: Contribution to journalArticle

Abstract

Background: ADAMTS13 deficiency causes accumulation of unusually large von Willebrand factor molecules, which cross-link platelets in the circulation or on the endothelial surface. This process of intravascular agglutination leads to the microangiopathy thrombotic thrombocytopenic purpura (TTP). Most TTP patients have acquired anti-ADAMTS13 autoantibodies that inhibit enzyme function and/or clear it from the circulation. However, the reason for ADAMTS13 deficiency is not always easily identified in a subset of patients. Objectives: To determine the origin of ADAMTS13 deficiency in a case of acquired TTP. Methods: Western blotting of ADAMTS13 in plasmas from acute and remission phases was used. Results: The ADAMTS13 deficiency was not caused by mutations or (detectable) autoantibodies; however, an abnormal ADAMTS13 truncated fragment (100 kDa) was found in acute-phase but not remission-phase plasma. This fragment resulted from enzymatic proteolysis, as recombinant ADAMTS13 was also cleaved when in the presence of acute-phase but not remission-phase plasma. Inhibitor screening showed that ADAMTS13 was cleaved by a serine protease that could be dose-dependently inhibited by addition of exogenous α2-antiplasmin. Examination of the endogenous α2-antiplasmin antigen and activity confirmed deficiency of α2-antiplasmin function in acute-phase but not remission-phase plasma. To investigate the possibility of ADAMTS13 cleavage by plasmin in plasma, urokinase-type plasminogen activator was added to an (unrelated) congenital α2-antiplasmin-deficient plasma sample to activate plasminogen. This experiment confirmed cleavage of endogenous ADAMTS13 similar to that observed in our TTP patient. Conclusion: We report the first acquired TTP patient with cleaved ADAMTS13 and show that plasmin is involved.

Original languageEnglish
Pages (from-to)2053-2062
Number of pages10
JournalJournal of Thrombosis and Haemostasis
Volume8
Issue number9
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Thrombotic Thrombocytopenic Purpura
Fibrinolysin
Antifibrinolytic Agents
Autoantibodies
Erythrocyte Aggregation
Plasminogen
Urokinase-Type Plasminogen Activator
von Willebrand Factor
Serine Proteases
Proteolysis
Blood Platelets
Western Blotting
Antigens
Mutation
Enzymes

Keywords

  • ADAMTS13
  • Plasmin
  • TTP

ASJC Scopus subject areas

  • Hematology

Cite this

Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. / Feys, H. B.; Vandeputte, N.; Palla, R.; Peyvandi, F.; Peerlinck, K.; Deckmyn, H.; Lijnen, H. R.; Vanhoorelbeke, K.

In: Journal of Thrombosis and Haemostasis, Vol. 8, No. 9, 09.2010, p. 2053-2062.

Research output: Contribution to journalArticle

Feys, H. B. ; Vandeputte, N. ; Palla, R. ; Peyvandi, F. ; Peerlinck, K. ; Deckmyn, H. ; Lijnen, H. R. ; Vanhoorelbeke, K. / Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. In: Journal of Thrombosis and Haemostasis. 2010 ; Vol. 8, No. 9. pp. 2053-2062.
@article{c2393e5475844af3812abb2767526edf,
title = "Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura",
abstract = "Background: ADAMTS13 deficiency causes accumulation of unusually large von Willebrand factor molecules, which cross-link platelets in the circulation or on the endothelial surface. This process of intravascular agglutination leads to the microangiopathy thrombotic thrombocytopenic purpura (TTP). Most TTP patients have acquired anti-ADAMTS13 autoantibodies that inhibit enzyme function and/or clear it from the circulation. However, the reason for ADAMTS13 deficiency is not always easily identified in a subset of patients. Objectives: To determine the origin of ADAMTS13 deficiency in a case of acquired TTP. Methods: Western blotting of ADAMTS13 in plasmas from acute and remission phases was used. Results: The ADAMTS13 deficiency was not caused by mutations or (detectable) autoantibodies; however, an abnormal ADAMTS13 truncated fragment (100 kDa) was found in acute-phase but not remission-phase plasma. This fragment resulted from enzymatic proteolysis, as recombinant ADAMTS13 was also cleaved when in the presence of acute-phase but not remission-phase plasma. Inhibitor screening showed that ADAMTS13 was cleaved by a serine protease that could be dose-dependently inhibited by addition of exogenous α2-antiplasmin. Examination of the endogenous α2-antiplasmin antigen and activity confirmed deficiency of α2-antiplasmin function in acute-phase but not remission-phase plasma. To investigate the possibility of ADAMTS13 cleavage by plasmin in plasma, urokinase-type plasminogen activator was added to an (unrelated) congenital α2-antiplasmin-deficient plasma sample to activate plasminogen. This experiment confirmed cleavage of endogenous ADAMTS13 similar to that observed in our TTP patient. Conclusion: We report the first acquired TTP patient with cleaved ADAMTS13 and show that plasmin is involved.",
keywords = "ADAMTS13, Plasmin, TTP",
author = "Feys, {H. B.} and N. Vandeputte and R. Palla and F. Peyvandi and K. Peerlinck and H. Deckmyn and Lijnen, {H. R.} and K. Vanhoorelbeke",
year = "2010",
month = "9",
doi = "10.1111/j.1538-7836.2010.03942.x",
language = "English",
volume = "8",
pages = "2053--2062",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura

AU - Feys, H. B.

AU - Vandeputte, N.

AU - Palla, R.

AU - Peyvandi, F.

AU - Peerlinck, K.

AU - Deckmyn, H.

AU - Lijnen, H. R.

AU - Vanhoorelbeke, K.

PY - 2010/9

Y1 - 2010/9

N2 - Background: ADAMTS13 deficiency causes accumulation of unusually large von Willebrand factor molecules, which cross-link platelets in the circulation or on the endothelial surface. This process of intravascular agglutination leads to the microangiopathy thrombotic thrombocytopenic purpura (TTP). Most TTP patients have acquired anti-ADAMTS13 autoantibodies that inhibit enzyme function and/or clear it from the circulation. However, the reason for ADAMTS13 deficiency is not always easily identified in a subset of patients. Objectives: To determine the origin of ADAMTS13 deficiency in a case of acquired TTP. Methods: Western blotting of ADAMTS13 in plasmas from acute and remission phases was used. Results: The ADAMTS13 deficiency was not caused by mutations or (detectable) autoantibodies; however, an abnormal ADAMTS13 truncated fragment (100 kDa) was found in acute-phase but not remission-phase plasma. This fragment resulted from enzymatic proteolysis, as recombinant ADAMTS13 was also cleaved when in the presence of acute-phase but not remission-phase plasma. Inhibitor screening showed that ADAMTS13 was cleaved by a serine protease that could be dose-dependently inhibited by addition of exogenous α2-antiplasmin. Examination of the endogenous α2-antiplasmin antigen and activity confirmed deficiency of α2-antiplasmin function in acute-phase but not remission-phase plasma. To investigate the possibility of ADAMTS13 cleavage by plasmin in plasma, urokinase-type plasminogen activator was added to an (unrelated) congenital α2-antiplasmin-deficient plasma sample to activate plasminogen. This experiment confirmed cleavage of endogenous ADAMTS13 similar to that observed in our TTP patient. Conclusion: We report the first acquired TTP patient with cleaved ADAMTS13 and show that plasmin is involved.

AB - Background: ADAMTS13 deficiency causes accumulation of unusually large von Willebrand factor molecules, which cross-link platelets in the circulation or on the endothelial surface. This process of intravascular agglutination leads to the microangiopathy thrombotic thrombocytopenic purpura (TTP). Most TTP patients have acquired anti-ADAMTS13 autoantibodies that inhibit enzyme function and/or clear it from the circulation. However, the reason for ADAMTS13 deficiency is not always easily identified in a subset of patients. Objectives: To determine the origin of ADAMTS13 deficiency in a case of acquired TTP. Methods: Western blotting of ADAMTS13 in plasmas from acute and remission phases was used. Results: The ADAMTS13 deficiency was not caused by mutations or (detectable) autoantibodies; however, an abnormal ADAMTS13 truncated fragment (100 kDa) was found in acute-phase but not remission-phase plasma. This fragment resulted from enzymatic proteolysis, as recombinant ADAMTS13 was also cleaved when in the presence of acute-phase but not remission-phase plasma. Inhibitor screening showed that ADAMTS13 was cleaved by a serine protease that could be dose-dependently inhibited by addition of exogenous α2-antiplasmin. Examination of the endogenous α2-antiplasmin antigen and activity confirmed deficiency of α2-antiplasmin function in acute-phase but not remission-phase plasma. To investigate the possibility of ADAMTS13 cleavage by plasmin in plasma, urokinase-type plasminogen activator was added to an (unrelated) congenital α2-antiplasmin-deficient plasma sample to activate plasminogen. This experiment confirmed cleavage of endogenous ADAMTS13 similar to that observed in our TTP patient. Conclusion: We report the first acquired TTP patient with cleaved ADAMTS13 and show that plasmin is involved.

KW - ADAMTS13

KW - Plasmin

KW - TTP

UR - http://www.scopus.com/inward/record.url?scp=77956486046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956486046&partnerID=8YFLogxK

U2 - 10.1111/j.1538-7836.2010.03942.x

DO - 10.1111/j.1538-7836.2010.03942.x

M3 - Article

C2 - 20553378

AN - SCOPUS:77956486046

VL - 8

SP - 2053

EP - 2062

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 9

ER -